Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

SUNLENCA DIN 02532476

Status: Marketed
Holder: GILEAD SCIENCES CANADA INC
Molecule: LENACAPAVIR (LENACAPAVIR SODIUM)
Available to quote

Health Canada record

Active ingredient(s)LENACAPAVIR (LENACAPAVIR SODIUM) 309 MG
Dosage formSolution
RouteSubcutaneous
SchedulePRESCRIPTION
ClassHuman
ATCJ05AX31 LENACAPAVIR
Original market date15-Mar-2023
Current status date15-Mar-2023
SourceHealth Canada DPD

Establishment licence of the holder

Gilead Sciences Canada Inc — licence 101221, currently licensed, last inspection rating C (2022-09-20).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing LENACAPAVIR (LENACAPAVIR SODIUM)

DINProductCompanyFormStrengthStatus
02532468SUNLENCAGILEAD SCIENCES CANADA INCTabletLENACAPAVIR (LENACAPAVIR SODIUM) 300 MGMarketed
02567202YEYTUOGILEAD SCIENCES CANADA INCTabletLENACAPAVIR (LENACAPAVIR SODIUM) 300 MGApproved
02567210YEYTUOGILEAD SCIENCES CANADA INCSolutionLENACAPAVIR (LENACAPAVIR SODIUM) 309 MGApproved

Notices of Compliance

NOCDateSubmissionReason
293682022-11-02New Drug Submission (NDS)
Request a quote for SUNLENCA

How to read a Canadian DIN record